Compare QCLS & MODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCLS | MODD |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 28.5M |
| IPO Year | N/A | 2019 |
| Metric | QCLS | MODD |
|---|---|---|
| Price | $3.63 | $4.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 240.8K | 119.8K |
| Earning Date | 04-15-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.12 |
| 52 Week High | $8.17 | $6.16 |
| Indicator | QCLS | MODD |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 44.24 |
| Support Level | $3.45 | $0.31 |
| Resistance Level | $3.90 | $5.84 |
| Average True Range (ATR) | 0.26 | 0.68 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 15.87 | 9.09 |
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.